Living Donor Liver Transplantation for Neoadjuvant-Treated, Unresectable Intrahepatic Cholangiocarcinoma (LIVINCA): Study Protocol for a One-Armed, Monocentric, Non-Randomized Trial
Oncology Research and Treatment · 2025
DOI: 10.1159/000545871 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Oncology Research and Treatment, 2025. Verfasst von Laura Schwenk und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of General, Visceral and Vascular Surgery, Jena University Hospital, Jena, Germany. Hauptthemen laut MEDLINE: Bile Duct Neoplasms, Cholangiocarcinoma, Liver Transplantation, Living Donors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
Introduction
Intrahepatic cholangiocarcinoma has demonstrated a consistently increasing incidence in recent years. In cases of unresectability, palliative chemotherapy often remains the only option, typically associated with a poor prognosis. Liver transplantation might be an option for otherwise unresectable intrahepatic cholangiocarcinoma. We aimed to conduct a prospective, non-randomized study to further explore the effects of living donor liver transplantation in the treatment of unresectable neoadjuvant-treated intrahepatic cholangiocarcinoma.
Methods
Patients with unresectable intrahepatic cholangiocarcinoma having a stable disease or tumor regression after systemic chemotherapy without an extrahepatic tumor burden are suitable for study inclusion. For a local control of the tumor, an additional local ablative therapy in means of a selective internal radiotherapy is mandatory. The main concept of the surgical procedure is a liver transplantation using the left (segments II–IV) or the right lobe (segments V–VIII) of a living donor. In oncosurgical optimal conditions, a two-staged hepatectomy combined with the (initially) auxiliary transplantation of a left lateral lobe of a living donor is the possible. The patient recruitment will start in September 2024.
Conclusion
The design of the LIVINCA study may provide patients with otherwise unresectable intrahepatic cholangiocarcinoma a chance for a curative treatment option. This procedure does not reduce the deceased donor organ supply because living donation is the primary treatment option in these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General, Visceral and Vascular Surgery, Jena University Hospital, Jena, Germany.
- Interdisciplinary Center for Clinical Research (IZKF), Jena University Hospital, Jena, Germany.
Zitieren
APA
Schwenk, L., Dondorf, F., Rohland, O., Ali-Deeb, A., Settmacher, U., Rauchfuß, F., & Schwenk, L. (2025). Living Donor Liver Transplantation for Neoadjuvant-Treated, Unresectable Intrahepatic Cholangiocarcinoma (LIVINCA): Study Protocol for a One-Armed, Monocentric, Non-Randomized Trial. Oncology Research and Treatment. https://doi.org/10.1159/000545871
Vancouver
Schwenk L, Dondorf F, Rohland O, Ali-Deeb A, Settmacher U, Rauchfuß F, et al. Living Donor Liver Transplantation for Neoadjuvant-Treated, Unresectable Intrahepatic Cholangiocarcinoma (LIVINCA): Study Protocol for a One-Armed, Monocentric, Non-Randomized Trial. Oncology Research and Treatment. 2025. doi:10.1159/000545871
BibTeX
@article{Schwenk2025,
author = {Schwenk, Laura and Dondorf, Felix and Rohland, Oliver and Ali-Deeb, Aladdin and Settmacher, Utz and Rauchfuß, Falk and Schwenk, Laura},
title = {Living Donor Liver Transplantation for Neoadjuvant-Treated, Unresectable Intrahepatic Cholangiocarcinoma (LIVINCA): Study Protocol for a One-Armed, Monocentric, Non-Randomized Trial},
journal = {Oncology Research and Treatment},
year = {2025},
doi = {10.1159/000545871}
}
EUVIMED